Stada Arzneimittel
Founded Year
1895Stage
Take Private | IPOMissing: Stada Arzneimittel's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Stada Arzneimittel's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Stada Arzneimittel Patents
Stada Arzneimittel has filed 3 patents.
The 3 most popular patent topics include:
- Autoimmune diseases
- Digestive system
- Inflammations
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/30/2017 | 1/26/2021 | Gastrointestinal tract disorders, Inflammations, Autoimmune diseases, Immune system, Digestive system | Grant |
Application Date | 6/30/2017 |
|---|---|
Grant Date | 1/26/2021 |
Title | |
Related Topics | Gastrointestinal tract disorders, Inflammations, Autoimmune diseases, Immune system, Digestive system |
Status | Grant |
Latest Stada Arzneimittel News
May 25, 2023
24-05-2023 German generics major STADA Arzneimittel (SAZ: Xetra) today revealed that, following a six-day inspection, the US Food and Drug Administration (FDA) has approved the STADA-controlled entity as a manufacturing and storage site for Retacrit (epoetin alfa-epbx) drug substance, at the Norbitec biologics facility in Uetersen, Germany. In 2018, Retacrit became the first available biosimilar to Procrit (epoetin alfa) and Epogen (epoetin alfa) from Amgen (Nasdaq:… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
Stada Arzneimittel Frequently Asked Questions (FAQ)
When was Stada Arzneimittel founded?
Stada Arzneimittel was founded in 1895.
Where is Stada Arzneimittel's headquarters?
Stada Arzneimittel's headquarters is located at Stadastrasse 2-18, Bad Vibel.
What is Stada Arzneimittel's latest funding round?
Stada Arzneimittel's latest funding round is Take Private.
Who are the investors of Stada Arzneimittel?
Investors of Stada Arzneimittel include Bain Capital and Cinven.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.